The invention relates to application of an FUNDC1 inhibitor in preparation of a
medicine for preventing and treating
skin light injury, and the FUNDC1 inhibitor relieves, alleviates or prevents and treats the
skin light injury by inhibiting or reducing expression of FUNDC1. A
light damage model is established by irradiating
mouse skin and
HaCaT cells through UVB, expression of FUNDC1 is reduced after UVB treatment, in view of the fact that UVB-induced
light damage is aggravated by FUNDC1 overexpression, whether knock-down FUNDC1 can protect the
HaCaT cells and the mouse model from the UVB-induced
light damage or not is explored, after the FUNDC1 is knocked down, the
cell survival rate is increased to 80%, and compared with a UVB group, the
cell survival rate is increased to 80%. The ROS level,
apoptosis and gamma H2Ax expression are reduced; after UVB
irradiation, FUNDC1 knock-down also alleviates mitochondrial damage, which shows that mitochondrial distribution is uniformly distributed along
cell nucleuses, and mitochondrial
membrane potential repolarization and mtROS accumulation are reduced. According to the invention, the FUNDC1-mediated mitochondrial
autophagy is intervened, and the mitochondrial
apoptosis pathway is regulated and controlled, so that the UVB-induced mitochondrial injury and light injury can be protected, and a potential target spot is provided for relieving the
skin light injury in the future.